Clinical Evaluation of Nasopharyngeal, Midturbinate Nasal and Oropharyngeal Swabs for the Detection of SARS-CoV-2
Overview
Microbiology
Pathology
Affiliations
In the setting of supply chain shortages of nasopharyngeal (NP) swabs, we sought to compare the ability of nasopharyngeal, midturbinate nasal, and oropharyngeal swabs (NPS, MTS, and OPS) to detect SARS-CoV-2. Community and hospitalized participants post-COVID-19 diagnosis were swabbed and tested for SARS-CoV-2 by PCR. Thirty-six participants had all 3 swabs collected. Using detection at any site as the standard, the percent positive agreements were 90% (95% CI 74.4-96.5), 80% (70.3-94.7) and 87% (62.7-90.5) for NPS, MTS, and OPS, respectively. Subsequently, 43 participants had OPS and NPS collected. Thirty-nine were positive with a percent positive agreement of 82.1% (95% CI 67.3-91.0) for OPS and 87.2% (73.3-94.4) for NPS. Combining all 79 patients tested, 67 were positive at either site with a positive agreement was 86.5% (76.4-92.7) for OPS and 91.1% (81.8-95.8) for NPS. OPS are an acceptable alternative to NPS for the detection of SARS-CoV-2 infections.
Liu C, Shen W, Xie H, Li Y, Cui R, Wu R Front Public Health. 2024; 11:1294341.
PMID: 38249400 PMC: 10796989. DOI: 10.3389/fpubh.2023.1294341.
Jung E, Lee S, Shin S, Kim J, Woo H, Cho E Ann Lab Med. 2023; 43(5):434-442.
PMID: 37080744 PMC: 10151282. DOI: 10.3343/alm.2023.43.5.434.
Fernandez-Montero A, Zuaznabar J, Pina-Sanchez M, Maestro S, Martin-Navarro L, Munoz-Rodriguez N Front Cell Infect Microbiol. 2023; 13:1110467.
PMID: 36761900 PMC: 9905247. DOI: 10.3389/fcimb.2023.1110467.
Larsen K, Jensen M, Homoe A, Arndal E, Samuelsen G, Koch A Diagnostics (Basel). 2023; 13(2).
PMID: 36673094 PMC: 9857511. DOI: 10.3390/diagnostics13020283.
Achenbach C, Caputo M, Hawkins C, Balmert L, Qi C, Odorisio J PLoS One. 2022; 17(6):e0270060.
PMID: 35709204 PMC: 9202852. DOI: 10.1371/journal.pone.0270060.